Intellia Therapeutics (NASDAQ:NTLA) Receives “Neutral” Rating from Wedbush

Wedbush reissued their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Tuesday,Benzinga reports. The firm currently has a $12.00 price objective on the stock.

NTLA has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Tuesday, April 21st. Truist Financial raised shares of Intellia Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Robert W. Baird upped their price target on shares of Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, April 27th. Wall Street Zen raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, The Goldman Sachs Group increased their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research note on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $20.36.

Intellia Therapeutics Stock Down 3.0%

Shares of NASDAQ:NTLA opened at $13.99 on Tuesday. The company’s 50 day moving average price is $13.67 and its two-hundred day moving average price is $12.15. Intellia Therapeutics has a 12-month low of $6.83 and a 12-month high of $28.25. The firm has a market cap of $1.69 billion, a PE ratio of -3.95 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 55.63%. The firm had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. On average, research analysts expect that Intellia Therapeutics will post -3.5 EPS for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Comerica Bank increased its position in Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the period. Headlands Technologies LLC acquired a new position in Intellia Therapeutics in the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $30,000. Advisory Services Network LLC acquired a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $33,000. Finally, Spire Wealth Management acquired a new position in Intellia Therapeutics in the 4th quarter valued at approximately $37,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.